Virgin Galactic (NYSE:SPCE) flew Richard Branson into space on Sunday in the first commercial passenger space flight ever, and the voyage was very successful. In response to this event, SPCE stock popped about 7% in premarket. However, it quickly reversed course and is now trading down approximately 14% after the company disclosed it would be
Stocks to buy
Many analysts believe current stock valuations resemble the dot-com era. The market’s day-to-day movements are certainly turbulent. But in the long run, returns tend to follow somewhat predictable upward trends. Regardless, picking stocks to buy in this environment becomes a tricky proposition. You do not want to be overpaying for a company with little to
It’s fair to say that the plant-based foods craze kicked off in earnest with the rise of Beyond Meat (NASDAQ:BYND). There are other businesses in this niche, of course, but the trading volumes of BYND stock prove that Beyond Meat is the leader in investable and digestible meatless fare. Source: Shutterstock And here’s what’s amazing about
Investing in clinical-stage biopharmaceutical companies can be hit-or-miss. Other companies are advancing Covid-19 vaccines, of course, but Ocugen (NASDAQ:OCGN) is unique and OCGN stock is still highly affordable. Source: Shutterstock Before taking a position in Ocugen, though, you’ll definitely want to conduct your due diligence. Biotech stocks can move fast — and by that, I mean
It’s a pleasure to bring you the best hidden gems in the market, especially when they’re easily affordable. Recon Technology (NASDAQ:RCON) fits that description, as RCON stock recently came down to a very attractive price point. Source: Shutterstock.com As you might have heard, buying where there’s “blood in the streets” can be a highly profitable strategy.
Editor’s note: This column is part of InvestorPlace.com’s Best Stocks for 2021 contest. Eric Fry’s pick for the contest is Osisko Gold Royalties (NYSE:OR). Source: Shutterstock Since the last time we talked in early April, when this stock was down 10% year-to-date, Osisko Gold Royalties has staged a comeback to notch a respectable 6% gain year-to-date at the
Facebook (NASDAQ:FB) stock has been on a roll. So far this year FB stock is up 26.5% as of July 9 when it closed at $350.42, up by $77.26 from its close of $273.16 on Dec. 31. This is close to my original target price of $374.53 that I forecast on Feb. 9 (up from
Nio (NYSE:NIO) stock has been weak in recent weeks thanks to concerns related to China regulation. Long story short, the Chinese government has been cracking down on its own “Big Tech” companies that have been seeking fundraising in the United States via American exchange listings. Source: Andy Feng/Shutterstock.com Ride-sharing platform Didi (NYSE:DIDI) has been at
Just as I predicted in my last article on ViacomCBS (NASDAQ:VIAC), the company produced a large increase in free cash flow (FCF) during Q1. On May 6, the company presented its latest earnings and cash flow release. As a result of its astounding jump in FCF, I now estimate that VIAC stock is worth at
There has been a lot of noise in the market in 2021. The rise and fall of so-called social media “meme” stocks like Canadian cannabis producer Tilray (NASDAQ:TLRY) stock may be the noisiest phenomenon of the first half of the year. Source: Jarretera / Shutterstock.com Meme stock mania has focused mainly on stocks that have
Everyone knows about how Nikola (NASDAQ:NKLA) stock fell from its peak amid the ridiculous tenure of CEO Trevor Martin and his ignominious departure. Since then, the company lost its orders and other potential partners bailed out on the previous deals. NKLA stock has fallen to $13.40 as of March 25 from its previous peak of
Shares in hydrogen fuel system company Plug Power (NASDAQ:PLUG) have been a big mover in 2021. However, for the past two months, they’ve been going in the wrong direction. PLUG stock gained 950% in 2020, then started off 2021 with a 127% surge in the first three weeks. It’s been downhill since then, though. PLUG shares
After a bullish year of big gains for growth investors, market jitters have set in. The U.S. 10-year Treasury yield recently reached a 52-week high, now sitting above 1.7%. In January 2017, that yield was over 2.5%, and economists are debating whether we’ll soon see a return to those levels. But despite occasional pullbacks in
At the end of January, I recommended that investors looking to avoid the “dizzying valuations” that many tech names had reached consider fiber optic names, which could also be classified as 5G stocks. I pointed out that, “In a sense, the fiber optics sector is an obscure group within a partially forgotten catalyst” of 5G.
Red-hot Ocugen (NASDAQ:OCGN) stock has cooled off a bit lately. Right now, it appears that investors in OCGN stock are in wait-and-see mode. What are they waiting for? A few key catalysts that could take this stock much higher. Source: luchschenF / Shutterstock.com Indeed, shares of the pre-clinical biopharmaceutical company have traded sideways over the past
After Ayro (NASDAQ:AYRO) announced a promising partnership and unveiled a new electric vehicle (EV) that I believe has a great deal of potential, the outlook of AYRO stock continues to be very favorable. Source: Alexandru Nika / Shutterstock.com Further, certain aspects of Ayro’s recent sales of its new shares bode well for its stock price.
Despite an up-and-down performance so far in 2021, Nano Dimension (NASDAQ:NNDM) stock has had an extraordinary 12-month run. Source: shutterstock.com/Alex_Traksel The Israeli 3D printing company is up only 1.65% year-to-date, but that includes wild swings that saw the NNDM stock price soar by 83% and tumble by more than 50%. Over the last 12 months,
Founded during the financial crisis year of 2009, advertising automation platform Trade Desk (NASDAQ:TTD) has survived tough times and prevailed. Along with that, TTD stock traders have endured plenty of ups and downs, yet prospered in the long run. Source: BrightSpace / Shutterstock.com However, not every investor is 100% satisfied. That’s because the share price has
New Jersey-based Citius Pharmaceuticals (NASDAQ:CTXR) could simply be pigeonholed as a medical product company. But that’s an oversimplification. Prospective CTXR stock investors deserve a much more in-depth discussion of this fascinating company. Source: Iryna Imago / Shutterstock.com Citius describes itself as a “late-stage specialty pharmaceutical company” that develops and commercializes “critical care products, with a particular
Sentiment on Wall Street is somewhat sour. This is in spite of three out of four indices making new highs last week. Perception that stocks are suffering is overcoming the reality of the strength in equity. This is perhaps because of weakness in the largest mega-cap stocks in the Nasdaq. It’s the only index that